

The merchandise is currently classifiable under Harmonized Tariff Schedule of the United States (HTSUS) subheadings 2915.70.0110, 2915.70.0120, 2915.70.0150, 2915.90.1010, 2915.90.1050, 2916.15.1000, 2916.15.5100, 3823.11.0000, 3823.12.0000, 3823.19.2000, and 3823.19.4000 and may also enter under 3824.99.4190.

The HTSUS subheadings set forth above are provided for convenience and customs purposes only. The written description of the scope is dispositive.

Appendix II

List of Topics Discussed in the Preliminary Decision Memorandum

- I. Summary
- II. Background
- III. Injury Test
- IV. Diversification of Indonesia's Economy
- V. Subsidies Valuation
- VI. Benchmarks and Interest Rates
- VII. Analysis of Programs
- VIII. Recommendation

[FR Doc. 2026-14871 Filed 7-22-26; 8:45 am]

BILLING CODE 3510-DS-P

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No.: PTO-P-2026-0499]

Grant of Interim Extension of the Term of U.S. Patent No. 8,461,196; Centanafadine Hydrochloride

AGENCY: United States Patent and Trademark Office; Department of Commerce.

ACTION: Notice of interim patent term extension.

SUMMARY: The United States Patent and Trademark Office has issued an order granting a one-year interim extension of the term of U.S. Patent No. 8,461,196 ('196 patent).

FOR FURTHER INFORMATION CONTACT: Raul Tamayo, Senior Legal Advisor, Office of Patent Legal Administration, at 571-272-7728 or raul.tamayo@uspto.gov.

SUPPLEMENTARY INFORMATION: 35 U.S.C. 156 generally provides that the term of a patent may be extended for a period of up to five years, if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review. 35 U.S.C. 156(d)(5) generally provides that the term of such a patent may be extended for no more than five interim periods of up to one year each, if the approval phase of the regulatory review period (RRP) is reasonably expected to extend beyond the expiration date of the patent.

On July 7, 2026, Otsuka Pharmaceutical Co., Ltd., the agent of the owner of record of the '196 patent,

i.e., Otsuka America Pharmaceutical, Inc., timely filed an application under 35 U.S.C. 156(d)(5) for a first interim extension of the term of the '196 patent. The '196 patent claims the drug product centanafadine hydrochloride. The application indicates that a RRP as described in 35 U.S.C. 156(g)(1)(B)(ii) for centanafadine hydrochloride is ongoing before the Food and Drug Administration for permission to market and use the drug product commercially.

Review of the application indicates that, except for permission to market or use the drug product commercially, the '196 patent would be eligible for an extension of its term under 35 U.S.C. 156. Because it appears reasonable to expect that the RRP will continue beyond the original expiration date of the '196 patent, *i.e.*, July 25, 2026, interim extension of the patent's term under 35 U.S.C. 156(d)(5) is appropriate.

A first interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 8,461,196 is granted for a period of one year from the original expiration date of the patent.

Stefanos Karmis,

Acting Deputy Commissioner for Patents, United States Patent and Trademark Office.

[FR Doc. 2026-14941 Filed 7-22-26; 8:45 am]

BILLING CODE 3510-16-P

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No.: PTO-P-2026-0497]

Grant of Interim Extension of the Term of U.S. Patent No. 9,737,506; Centanafadine Hydrochloride

AGENCY: United States Patent and Trademark Office; Department of Commerce.

ACTION: Notice of interim patent term extension.

SUMMARY: The United States Patent and Trademark Office has issued an order granting a one-year interim extension of the term of U.S. Patent No. 9,737,506 ('506 patent).

FOR FURTHER INFORMATION CONTACT: Raul Tamayo, Senior Legal Advisor, Office of Patent Legal Administration, at 571-272-7728 or raul.tamayo@uspto.gov.

SUPPLEMENTARY INFORMATION: 35 U.S.C. 156 generally provides that the term of a patent may be extended for a period of up to five years, if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review. 35 U.S.C. 156(d)(5) generally provides that the term of such a patent may be

extended for no more than five interim periods of up to one year each, if the approval phase of the regulatory review period (RRP) is reasonably expected to extend beyond the expiration date of the patent.

On July 7, 2026, Otsuka Pharmaceutical Co., Ltd., the agent of the owner of record of the '506 patent, *i.e.*, Otsuka America Pharmaceutical, Inc., timely filed an application under 35 U.S.C. 156(d)(5) for a first interim extension of the term of the '506 patent. The '506 patent claims methods of using the drug product centanafadine hydrochloride. The application indicates that a RRP as described in 35 U.S.C. 156(g)(1)(B)(ii) for centanafadine hydrochloride is ongoing before the Food and Drug Administration for permission to market and use the drug product commercially.

Review of the application indicates that, except for permission to market or use the drug product commercially, the '506 patent would be eligible for an extension of its term under 35 U.S.C. 156. Because it appears reasonable to expect that the RRP will continue beyond the original expiration date of the '506 patent, *i.e.*, July 25, 2026, interim extension of the patent's term under 35 U.S.C. 156(d)(5) is appropriate.

A first interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 9,737,506 is granted for a period of one year from the original expiration date of the patent.

Stefanos Karmis,

Acting Deputy Commissioner for Patents, United States Patent and Trademark Office.

[FR Doc. 2026-14940 Filed 7-22-26; 8:45 am]

BILLING CODE 3510-16-P

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No.: PTO-P-2026-0496]

Grant of Interim Extension of the Term of U.S. Patent No. 8,877,798; Centanafadine Hydrochloride

AGENCY: United States Patent and Trademark Office; Department of Commerce.

ACTION: Notice of interim patent term extension.

SUMMARY: The United States Patent and Trademark Office has issued an order granting a one-year interim extension of the term of U.S. Patent No. 8,877,798 ('798 patent).

FOR FURTHER INFORMATION CONTACT: Raul Tamayo, Senior Legal Advisor, Office of Patent Legal Administration, at 571-272-7728 or raul.tamayo@uspto.gov.

SUPPLEMENTARY INFORMATION: 35 U.S.C. 156 generally provides that the term of a patent may be extended for a period of up to five years, if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review. 35 U.S.C. 156(d)(5) generally provides that the term of such a patent may be extended for no more than five interim periods of up to one year each, if the approval phase of the regulatory review period (RRP) is reasonably expected to extend beyond the expiration date of the patent.

On July 7, 2026, Otsuka Pharmaceutical Co., Ltd., the agent of the owner of record of the '798 patent, *i.e.*, Otsuka America Pharmaceutical, Inc., timely filed an application under 35 U.S.C. 156(d)(5) for a first interim extension of the term of the '798 patent. The '798 patent claims the drug product centanafadine hydrochloride. The application indicates that a RRP as described in 35 U.S.C. 156(g)(1)(B)(ii) for centanafadine hydrochloride is ongoing before the Food and Drug Administration for permission to market and use the drug product commercially.

Review of the application indicates that, except for permission to market or use the drug product commercially, the '798 patent would be eligible for an extension of its term under 35 U.S.C. 156. Because it appears reasonable to expect that the RRP will continue beyond the original expiration date of the '798 patent, *i.e.*, July 25, 2026, interim extension of the patent's term under 35 U.S.C. 156(d)(5) is appropriate.

A first interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 8,877,798 is granted for a period of one year from the original expiration date of the patent.

Stefanos Karmis,

*Acting Deputy Commissioner for Patents,
United States Patent and Trademark Office.*

[FR Doc. 2026-14939 Filed 7-22-26; 8:45 am]

BILLING CODE 3510-16-P

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No.: PTO-P-2026-0498]

Grant of Interim Extension of the Term of U.S. Patent No. 9,205,074; Centanafadine Hydrochloride

AGENCY: United States Patent and Trademark Office; Department of Commerce.

ACTION: Notice of interim patent term extension.

SUMMARY: The United States Patent and Trademark Office has issued an order granting a one-year interim extension of the term of U.S. Patent No. 9,205,074 ('074 patent).

FOR FURTHER INFORMATION CONTACT: Raul Tamayo, Senior Legal Advisor, Office of Patent Legal Administration, at 571-272-7728 or raul.tamayo@uspto.gov.

SUPPLEMENTARY INFORMATION: 35 U.S.C. 156 generally provides that the term of a patent may be extended for a period of up to five years, if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review. 35 U.S.C. 156(d)(5) generally provides that the term of such a patent may be extended for no more than five interim periods of up to one year each, if the approval phase of the regulatory review period (RRP) is reasonably expected to extend beyond the expiration date of the patent.

On July 7, 2026, Otsuka Pharmaceutical Co., Ltd., the agent of the owner of record of the '074 patent, *i.e.*, Otsuka America Pharmaceutical, Inc., timely filed an application under 35 U.S.C. 156(d)(5) for a first interim extension of the term of the '074 patent. The '074 patent claims methods of using the drug product centanafadine hydrochloride. The application indicates that a RRP as described in 35 U.S.C. 156(g)(1)(B)(ii) for centanafadine hydrochloride is ongoing before the Food and Drug Administration for permission to market and use the drug product commercially.

Review of the application indicates that, except for permission to market or use the drug product commercially, the '074 patent would be eligible for an extension of its term under 35 U.S.C. 156. Because it appears reasonable to expect that the RRP will continue beyond the original expiration date of the '074 patent, *i.e.*, July 25, 2026, interim extension of the patent's term under 35 U.S.C. 156(d)(5) is appropriate.

A first interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 9,205,074 is granted for a period of one year from the original expiration date of the patent.

Stefanos Karmis,

*Acting Deputy Commissioner for Patents,
United States Patent and Trademark Office.*

[FR Doc. 2026-14938 Filed 7-22-26; 8:45 am]

BILLING CODE 3510-16-P

COMMITTEE FOR PURCHASE FROM PEOPLE WHO ARE BLIND OR SEVERELY DISABLED

Procurement List; Proposed Additions and Deletions

AGENCY: Committee for Purchase From People Who Are Blind or Severely Disabled.

ACTION: Proposed additions to and deletions from the Procurement List.

SUMMARY: The Committee is proposing to add service(s) to the Procurement List that will be furnished by nonprofit agencies employing persons who are blind or have other severe disabilities, and delete product(s) and service(s) previously furnished by such agencies.

DATES: Comments must be received on or before: August 22, 2026.

ADDRESSES: Committee for Purchase From People Who Are Blind or Severely Disabled, 250 E Street SW, Suite 3100, Washington, DC 20024.

FOR FURTHER INFORMATION CONTACT: For further information or to submit comments contact: Michael R. Jurkowski, Telephone: (703) 489-1322, or email CMTEFedReg@AbilityOne.gov.

SUPPLEMENTARY INFORMATION: This notice is published pursuant to 41 U.S.C. 8503 (a)(2) and 41 CFR 51-2.3. Its purpose is to provide interested persons an opportunity to submit comments on the proposed actions.

Additions

In accordance with 41 CFR 51-5.3(b), the Committee intends to add the service requirements listed below to the Procurement List as a mandatory purchase only for contracting activities at the locations listed with the proposed qualified nonprofit agency as the authorized source of supply. Prior to adding the service to the Procurement List, the Committee will consider other pertinent information, including information from Government personnel and relevant comments from interested parties regarding the Committee's intent to geographically limit this services requirement.

The following service(s) are proposed for addition to the Procurement List for production by the nonprofit agencies listed:

Service(s)

Service Type: Janitorial Service

Mandatory For: Centers for Disease

Control and Prevention, Fort

Collins Colorado Campus, Fort

Collins, CO, 3156 Rampart Road,

FORT COLLINS, CO

Authorized Source of Supply:

ServiceSource, Inc., Oakton, VA